- Home
- RYOJ vs GRML Comparison
RYOJ vs GRML Comparison
Compare RYOJ & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RYOJ | GRML |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Japan | United States |
| Employees | N/A | 5 |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 34.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | RYOJ | GRML |
|---|---|---|
| Price | $5.16 | $0.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 82.5K | ★ 7.4M |
| Earning Date | 12-15-2025 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.56 | $0.16 |
| 52 Week High | $11.43 | $0.55 |
Technical Indicators
Market Signals| Indicator | RYOJ | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 40.29 |
| Support Level | $3.39 | $0.16 |
| Resistance Level | $6.49 | $0.30 |
| Average True Range (ATR) | 0.74 | 0.03 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 46.81 | 8.03 |
Price Performance
Historical ComparisonAbout RYOJ rYojbaba Co. Ltd.
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
About GRML Greenland Mines Ltd. Common Stock
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.